Today: 17 March 2026
RTX stock price rises as Singapore expansion plan puts focus back on repair capacity
3 February 2026
1 min read

RTX stock price rises as Singapore expansion plan puts focus back on repair capacity

NEW YORK, Feb 3, 2026, 15:41 ET — Regular session

RTX shares climbed roughly 1.1% to hit $203.22 in Tuesday afternoon trading, as investors weighed the company’s fresh move to grow its footprint in Singapore.

Timing is crucial as repair capacity has emerged as a key trading factor for major aerospace suppliers. Maintenance often means steady business, and when shop slots are limited, it can turn into the choke point delaying aircraft from returning to service.

RTX is zeroing in on Pratt & Whitney’s Geared Turbofan, or GTF, jet engines. Faster turnaround times could ease the strain on customers and help smooth out fleet disruptions.

The company plans to pour more than $139 million into Singapore, according to new memoranda of understanding signed with the Singapore Economic Development Board. Chris Haave, a company vice president, noted that “With more than 4,300 employees across 12 facilities, RTX is Singapore’s largest foreign aerospace and defense employer.” PR Newswire

Under the deals, Collins Aerospace will ramp up maintenance, repair, and overhaul work—known as MRO—linked to Boeing platforms. Pratt & Whitney plans to introduce a Fan Drive Gear System line for its GTF engines and boost coating capacity, the company said. Cindy Koh from the EDB described the investments as proof of RTX’s strong commitment to Singapore. Collins indicated the new capabilities should be fully up and running by 2030. RTX

Wall Street remains focused on the same narrative. Ronald Epstein at BofA Securities reaffirmed a Buy rating on RTX on Feb. 2, with a $230 price target, according to TipRanks. (A price target reflects where an analyst expects a stock to trade within the next year.) TipRanks

Defense news came through as RTX’s Raytheon unit landed a deal with the Defense Advanced Research Projects Agency. The contract calls for developing a sensing and targeting system designed to shield commercial shipping and naval logistics vessels from unmanned surface vehicles. “We are advancing critical security technologies for commercial shipping in regions like the Red Sea,” said Colin Whelan, Raytheon’s president of Advanced Technology. RTX

Raytheon announced it has wrapped up a company-funded ballistic test for the U.S. Army’s Next Generation Short Range Interceptor, or NGSRI, designed to replace the Stinger surface-to-air missile. “We continue to prioritize rapid learning and testing,” said Tom Laliberty, president of Land and Air Defense Systems at Raytheon. RTX

Defense stocks showed a split performance. Northrop Grumman jumped roughly 2.9%, General Dynamics climbed 2.3%, and L3Harris Technologies edged up 2.5%. Lockheed Martin, however, slipped 1.3%.

Investors will need confirmation that the Singapore build-out delivers usable capacity on time. Large MRO expansions often require time to hire, certify, and scale up, and returns can fluctuate if aircraft deliveries or repair demand shift.

RTX is set to release its quarterly results next, with Zacks Investment Research forecasting the first-quarter report on April 28. Zacks

For now, traders will be eyeing follow-up updates from the Singapore Air Show, looking closely for any signs that GTF shop capacity and repair turnaround times are improving.

Stock Market Today

  • NRx Pharmaceuticals Receives Preliminary FDA Bioequivalence Nod for Preservative-Free Ketamine
    March 17, 2026, 7:34 AM EDT. NRx Pharmaceuticals (Nasdaq: NRXP) announced the FDA Office of Generic Drugs has found no bioequivalence deficiencies in its preservative-free ketamine application, a critical step in the Abbreviated New Drug Application (ANDA) process. This tentative approval moves NRx closer to launching the first ketamine formulation without benzethonium chloride, a preservative linked to toxicity and no longer recognized as safe by FDA. The company expects final FDA approval by Summer 2026. NRx's product, produced in the U.S., aligns with FDA efforts to secure domestic supply chains for critical drugs. The preservative-free ketamine could become a branded generic, supported by recent patents. NRx continues developing a separate ketamine treatment for depression under a different FDA division.
Nvidia’s Huang says “no drama” with OpenAI as ChatGPT maker weighs other AI chips
Previous Story

Nvidia’s Huang says “no drama” with OpenAI as ChatGPT maker weighs other AI chips

Huang says Nvidia will still invest in OpenAI, dismisses ‘drama’ as Oracle exposure draws scrutiny
Next Story

Huang says Nvidia will still invest in OpenAI, dismisses ‘drama’ as Oracle exposure draws scrutiny

Go toTop